 |
Roger Jelliffe graduated from Harvard College in 1950 and Columbia University College of Physicians and Surgeons in 1954. He trained at University Hospitals of Cleveland, Ohio, and the VA Hospital, Cleveland, Ohio. He was an Instructor in Medicine at USC School of Medicine in 1961, then Assistant and Associate Professor, and has been Professor of Medicine since 1976. He was certified by the American Board of Internal Medicine in 1962 and its Subspecialty Board of Cardiovascular Disease in 1965. He developed the first computer software for modeling the pharmacokinetic behavior of digitalis glycosides and individualizing their dosage regimens in 1967. He was the first to relate the renal elimination rate constant of drugs to creatinine clearance. He developed the first method for estimating creatinine clearance when serum creatinine is rapidly changing. He founded the USC Laboratory of Applied Pharmacokinetics in 1973, and developed the USC*PACK computer programs for individualizing drug dosage regimens. His laboratory, with the mathematical strength of Alan Schumitzky, Professor of Mathematics at USC, David Bayard, Senior Scientist, Guidance, Control Section, Jet Propulsion Laboratorie, Pasadena CA, and Co-Director Michael Neely, Assistant Professor of Pediatrics at USC, developed the Research Resource for Population Modeling at the San Diego Supercomputer Center (and its satellite centers in Oslo and Singapore), the nonparametric adaptive grid (NPAG) population modeling approach, and the method of Multiple Model (MM) design of maximally precise dosage regimens for patients. The NPAG approach is naturally linked to “Multiple Model” (MM) dosage design. This has now become the MM-USCPACK clinical and research computer software. We have developed a Hybrid Bayesian procedure, a combination of maximum aposteriori probability and multiple model Bayesian analysis which can reach far out to unusual patients outside the range of the stated population parameters and get good fits with a density of (currently) 15 extra points about the MAP Bayesian estimate. This should add great capability and safety to the analysis of data from unusual patients. Dr. Jelliffe’s interest now is in nonlinear PK/PD population modeling, optimally coordinated combination drug dosage regimens for patient care, and in still newer methods of using the dose itself as an active partner to learn about the patient still more optimally while having to treat him/her at the same time. He has been author or co-author on 127 peer reviewed publications, has mentored over 100 visiting scientific scholars, and has mentored 1 sabbatical, 1 Master’s Student, 3 Ph.D candidates, and 3 mini-sabbaticals.
|
||||||||||||||||||||||||||||||||||||
